S&P 500   5,137.08
DOW   39,087.38
QQQ   445.61
Lawyers who successfully argued Musk pay package was illegal seek $5.6 billion in Tesla stock
Critical asset just had biggest fall on record (Ad)
Sports analytics may be outnumbered when it comes to artificial intelligence
In Senegal's capital, Nicaragua is a hot ticket among travel agents as migrants try to reach US
This is the #1 Stock to Buy for the AI Tidal Wave (Ad)
Norway's hospitalized king gets a pacemaker in Malaysia after falling ill during vacation
Head Start preschools aim to fight poverty, but their teachers struggle to make ends meet
This is the #1 Stock to Buy for the AI Tidal Wave (Ad)
What to watch for as China's major political meeting of the year gets underway
Chicago 'mansion' tax to fund homeless services stuck in legal limbo while on the ballot
S&P 500   5,137.08
DOW   39,087.38
QQQ   445.61
Lawyers who successfully argued Musk pay package was illegal seek $5.6 billion in Tesla stock
Critical asset just had biggest fall on record (Ad)
Sports analytics may be outnumbered when it comes to artificial intelligence
In Senegal's capital, Nicaragua is a hot ticket among travel agents as migrants try to reach US
This is the #1 Stock to Buy for the AI Tidal Wave (Ad)
Norway's hospitalized king gets a pacemaker in Malaysia after falling ill during vacation
Head Start preschools aim to fight poverty, but their teachers struggle to make ends meet
This is the #1 Stock to Buy for the AI Tidal Wave (Ad)
What to watch for as China's major political meeting of the year gets underway
Chicago 'mansion' tax to fund homeless services stuck in legal limbo while on the ballot
S&P 500   5,137.08
DOW   39,087.38
QQQ   445.61
Lawyers who successfully argued Musk pay package was illegal seek $5.6 billion in Tesla stock
Critical asset just had biggest fall on record (Ad)
Sports analytics may be outnumbered when it comes to artificial intelligence
In Senegal's capital, Nicaragua is a hot ticket among travel agents as migrants try to reach US
This is the #1 Stock to Buy for the AI Tidal Wave (Ad)
Norway's hospitalized king gets a pacemaker in Malaysia after falling ill during vacation
Head Start preschools aim to fight poverty, but their teachers struggle to make ends meet
This is the #1 Stock to Buy for the AI Tidal Wave (Ad)
What to watch for as China's major political meeting of the year gets underway
Chicago 'mansion' tax to fund homeless services stuck in legal limbo while on the ballot
S&P 500   5,137.08
DOW   39,087.38
QQQ   445.61
Lawyers who successfully argued Musk pay package was illegal seek $5.6 billion in Tesla stock
Critical asset just had biggest fall on record (Ad)
Sports analytics may be outnumbered when it comes to artificial intelligence
In Senegal's capital, Nicaragua is a hot ticket among travel agents as migrants try to reach US
This is the #1 Stock to Buy for the AI Tidal Wave (Ad)
Norway's hospitalized king gets a pacemaker in Malaysia after falling ill during vacation
Head Start preschools aim to fight poverty, but their teachers struggle to make ends meet
This is the #1 Stock to Buy for the AI Tidal Wave (Ad)
What to watch for as China's major political meeting of the year gets underway
Chicago 'mansion' tax to fund homeless services stuck in legal limbo while on the ballot

Nevro (NVRO) Stock Price, News & Analysis

$14.22
-0.34 (-2.34%)
(As of 03/1/2024 ET)
Today's Range
$14.13
$14.61
50-Day Range
$14.20
$22.31
52-Week Range
$13.98
$39.67
Volume
457,581 shs
Average Volume
463,759 shs
Market Capitalization
$517.58 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$23.23

Nevro MarketRank™ Stock Analysis

Analyst Rating
Hold
2.00 Rating Score
Upside/​Downside
63.4% Upside
$23.23 Price Target
Short Interest
Bearish
12.69% of Shares Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.30mentions of Nevro in the last 14 days
Based on 10 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
Growing
From ($2.53) to ($2.25) Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

2.18 out of 5 stars

Medical Sector

610th out of 950 stocks

Surgical & Medical Instruments Industry

67th out of 95 stocks


NVRO stock logo

About Nevro Stock (NYSE:NVRO)

Nevro Corp., a medical device company, provides products for patients suffering from chronic pain in the United States and internationally. The company develops and commercializes the Senza spinal cord stimulation (SCS) system, an evidence-based neuromodulation system for the treatment of chronic pain, as well as Senza II and Senza Omnia SCS systems. It also provides 10 kHz Therapy, which delivers neuromodulation solutions for treating chronic pain based on available clinical evidence. The company's Senza HFX iQ IPG system includes HFX iQ implantable pulse generator, HFX trial stimulator, and HFX iQ patient remote, as well as HFX App, a patient remote control and the wireless trialing system. In addition, it offers surpass surgical and percutaneous leads. The company sells its products through its direct sales force, and a network of sales agents and independent distributors. Nevro Corp. was incorporated in 2006 and is headquartered in Redwood City, California.

NVRO Stock Price History

NVRO Stock News Headlines

Nevro (NYSE:NVRO) Upgraded to "Hold" at StockNews.com
Critical asset just had biggest fall on record
What many consider America's critical financial asset suffers biggest fall on record. Expert says: "it's very bad for millions, protect yourself now."
Nevro (NYSE:NVRO) Stock Price Down 7% on Analyst Downgrade
Critical asset just had biggest fall on record
What many consider America's critical financial asset suffers biggest fall on record. Expert says: "it's very bad for millions, protect yourself now."
Nevro (NYSE:NVRO) Downgraded to Market Perform at Oppenheimer
StockNews.com Lowers Nevro (NYSE:NVRO) to Sell
Nevro just downgraded at Oppenheimer, here's why
Nevro (NYSE:NVRO) Shares Gap Down on Analyst Downgrade
Why Nevro Stock Lagged the Market on Thursday
Hold Rating on Nevro Corp Amid Modest Growth and Cautious 2024 Outlook
Analyst Scoreboard: 4 Ratings For Nevro
Nevro Corp. (NYSE:NVRO) Q4 2023 Earnings Call Transcript
Nevro: Q4 Earnings Snapshot
Nevro (NVRO) Reports Q4 Loss, Tops Revenue Estimates
See More Headlines
Receive NVRO Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Nevro and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
11/01/2023
Today
3/02/2024
Next Earnings (Estimated)
4/24/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Surgical & medical instruments
Sub-Industry
N/A
Fax
N/A
Employees
1,087
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$23.23
High Stock Price Target
$40.00
Low Stock Price Target
$15.00
Potential Upside/Downside
+63.4%
Consensus Rating
Hold
Rating Score (0-4)
2.00
Research Coverage
13 Analysts

Profitability

Net Income
$-92,210,000.00
Pretax Margin
-23.02%

Debt

Sales & Book Value

Annual Sales
$425.17 million
Book Value
$8.05 per share

Miscellaneous

Free Float
35,306,000
Market Cap
$517.58 million
Optionable
Optionable
Beta
0.91
12 Stocks Corporate Insiders are Abandoning Cover

If a company's CEO, COO, and CFO were all selling shares of their stock, would you want to know?

Get This Free Report

Key Executives

  • Mr. Roderick H. MacLeod (Age 57)
    Senior VP & CFO
    Comp: $729.61k
  • Mr. Kashif RashidMr. Kashif Rashid (Age 50)
    Senior VP, General Counsel & Corporate Secretary
    Comp: $703.35k
  • Mr. Kevin R. Thornal (Age 50)
    President, CEO & Director
  • Mr. Richard B. Carter (Age 53)
    Chief Accounting Officer
  • Mr. Christofer Christoforou (Age 54)
    Senior Vice President of Technical Operations
    Comp: $367.4k
  • Geeta Kaveti
    VP and Chief Compliance & Privacy Officer
  • Mr. Jon R. Shear
    Senior Vice President of Corporate Development
  • Meredith Vornholt
    Vice President of Global Marketing
  • Ms. Shana D. Ross M.B.A.
    Senior VP & Chief of Human Resources Officer
  • Dr. David Caraway M.D. (Age 67)
    Ph.D., Senior VP & Chief Medical Officer














NVRO Stock Analysis - Frequently Asked Questions

Should I buy or sell Nevro stock right now?

13 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Nevro in the last twelve months. There are currently 1 sell rating, 11 hold ratings and 1 buy rating for the stock. The consensus among Wall Street analysts is that investors should "hold" NVRO shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in NVRO, but not buy additional shares or sell existing shares.
View NVRO analyst ratings
or view top-rated stocks.

What is Nevro's stock price target for 2024?

13 Wall Street analysts have issued 12 month price objectives for Nevro's shares. Their NVRO share price targets range from $15.00 to $40.00. On average, they expect the company's share price to reach $23.23 in the next twelve months. This suggests a possible upside of 63.4% from the stock's current price.
View analysts price targets for NVRO
or view top-rated stocks among Wall Street analysts.

How have NVRO shares performed in 2024?

Nevro's stock was trading at $21.52 at the beginning of the year. Since then, NVRO shares have decreased by 33.9% and is now trading at $14.22.
View the best growth stocks for 2024 here
.

When is Nevro's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Wednesday, April 24th 2024.
View our NVRO earnings forecast
.

How were Nevro's earnings last quarter?

Nevro Corp. (NYSE:NVRO) posted its earnings results on Wednesday, November, 1st. The medical equipment provider reported ($0.65) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.77) by $0.12. The medical equipment provider earned $103.86 million during the quarter, compared to the consensus estimate of $95.87 million. Nevro had a negative trailing twelve-month return on equity of 30.22% and a negative net margin of 21.69%. The company's revenue was up 3.4% compared to the same quarter last year. During the same quarter last year, the business posted ($0.62) earnings per share.

What ETFs hold Nevro's stock?
What guidance has Nevro issued on next quarter's earnings?

Nevro issued an update on its first quarter 2024 earnings guidance on Wednesday, February, 21st. The company provided EPS guidance of for the period. The company issued revenue guidance of $97.0 million-$99.0 million, compared to the consensus revenue estimate of $98.7 million.

What is D. Keith Grossman's approval rating as Nevro's CEO?

9 employees have rated Nevro Chief Executive Officer D. Keith Grossman on Glassdoor.com. D. Keith Grossman has an approval rating of 68% among the company's employees.

What other stocks do shareholders of Nevro own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Nevro investors own include AT&T (T), NVIDIA (NVDA), AbbVie (ABBV), Walt Disney (DIS), General Electric (GE), Micron Technology (MU), Gilead Sciences (GILD), Advanced Micro Devices (AMD), Adobe (ADBE) and Intuitive Surgical (ISRG).

Who are Nevro's major shareholders?

Nevro's stock is owned by a number of retail and institutional investors. Top institutional investors include Vanguard Group Inc. (11.23%), Armistice Capital LLC (8.77%), Braidwell LP (4.91%), Goldman Sachs Group Inc. (2.89%), Goldman Sachs Group Inc. (2.88%) and Palo Alto Investors LP (2.07%). Insiders that own company stock include D Keith Grossman, Elizabeth H Weatherman, Kashif Rashid, Kevin C Oboyle, Leslie Stretch, Michael F Demane, Niamh Louise Pellegrini and Shawn Mccormick.
View institutional ownership trends
.

How do I buy shares of Nevro?

Shares of NVRO stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NYSE:NVRO) was last updated on 3/2/2024 by MarketBeat.com Staff